Eckert & Ziegler stock at EUR 12.32, market value EUR 773.4 million

Published on 10/09/2026 at 18:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

On October 9, 2026, Eckert & Ziegler stock was EUR 12.32 after EUR 12.22. Market value was EUR 773.4 million, with a P/E ratio of 15.7.

Key points in brief

Eckert & Ziegler traded at EUR 12.32 at Lang & Schwarz on October 9, 2026, up 0.82 percent from EUR 12.22.
The price stood 30.51 percent below the 52-week high of EUR 17.73 and 3.44 percent above the low of EUR 11.91.
Market capitalization was EUR 773.4 million, with a P/E ratio of 15.7 and a dividend yield of 2.0 percent.
Investing.com listed a 12-month average analyst target of EUR 21.60 from three analysts.
The next earnings release is scheduled for November 12, 2026.

Bauhaus-Designposter mit geometrischen Formen, Primärfarben und MEDTECH-Schriftzug — Eckert & Ziegler DE0005659700 Medizintechnik: Bauhaus-Poster mit geometrischen Grundfarben und Atomstruktur-Motiv sowie MEDTECH-Sektor-Schriftzug, Illustration mit AI erstellt.

Eckert & Ziegler (ISIN DE0005659700) was trading at EUR 12.32 at Lang & Schwarz on October 9, 2026 at 6:42 p.m. CEST, up 0.82 percent versus the prior close of EUR 12.22. The after-hours quote leaves the stock 30.51 percent below its 52-week high of EUR 17.73 and 3.44 percent above its low of EUR 11.91.

After-hours price stays near yearly low

The session snapshot places the Berlin medical technology company near the lower end of its 52-week range. Its market capitalization was EUR 773.4 million on October 9, 2026, while the latest finance quote showed 62,952 shares traded against an average volume of 116,621.

The bid stood at EUR 12.23 and the ask at EUR 12.41 at Lang & Schwarz. That spread matters for investors comparing the after-hours indication with the regular Xetra session, because the two prices describe different trading phases.

Valuation and analyst target

Eckert & Ziegler carried a P/E ratio of 15.7 and a dividend yield of 2.0 percent on October 9, 2026. The valuation is materially below the level implied by the analyst target, but the comparison uses the same EUR quotation currency and the same stock price.

Investing.com listed an average 12-month target of EUR 21.60 from three analysts. The target lies 75.32 percent above the Lang & Schwarz price of EUR 12.32, a numerical gap that gives the valuation discussion more weight than the modest daily move.

Comparison with peers

Eckert & Ziegler: plus 0.82 percent, P/E 15.7, market capitalization EUR 773.4 million
Sartorius (Xetra, EUR): plus 2.47 percent, P/E 89.6, market capitalization EUR 17.5 billion
DAX (Xetra, EUR): , ,

Next results date is November 12

MarketScreener lists November 12, 2026 as the next earnings release date for the third quarter of 2026. The date gives the market a defined checkpoint after the stock's move toward the lower end of its yearly range.

Eckert & Ziegler operates in healthcare and medical specialties, with activities spanning medical and isotope products. Its primary listing is Xetra, and the company is headquartered in Berlin.

The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.